Related Experiment Video

Updated: May 8, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.2K

MiR-27a-5p inhibits malignant progression of differentiated thyroid cancer by directly affecting the

Zilan Xie1,2,3,4, Jianqiu Liu5, Jiating Zhou1,2,3,4

  • 1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410078, China.

Journal of Endocrinological Investigation
|February 13, 2025
PubMed
Abstract

Insights

MicroRNA-27a-5p (miR-27a-5p) is downregulated in differentiated thyroid cancer (DTC) and targets SREBP1, inhibiting cancer progression and affecting TSH therapy outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Endocrinology

Background:

  • Differentiated thyroid cancer (DTC) is a common endocrine malignancy.
  • Understanding the molecular mechanisms underlying DTC progression is crucial for developing effective therapies.
  • MicroRNAs (miRNAs) play significant roles in cancer development and progression.

Purpose of the Study:

  • To investigate the expression of miR-27a-5p in DTC tissues.
  • To explore the relationship between miR-27a-5p, SREBP1 expression, and DTC malignant progression.
  • To determine the correlation of miR-27a-5p with TSH suppression therapy outcomes in DTC patients.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) to measure miR-27a-5p and SREBP1 expression in 75 DTC tissues.
  • Dual luciferase reporter gene assay to confirm the targeting of SREBP1 by miR-27a-5p.
  • Cell proliferation (MTS, plate clone formation), cell cycle, apoptosis (flow cytometry), migration, and invasion (scratch, Transwell assays) assays to assess the functional impact of miR-27a-5p.

Main Results:

  • miR-27a-5p expression was significantly downregulated in DTC tissues and negatively correlated with SREBP1 expression.
  • miR-27a-5p directly targets the 3'-UTR of SREBP1 mRNA.
  • Overexpression of miR-27a-5p suppressed cell proliferation, induced cell cycle arrest, increased apoptosis, and reduced cell migration and invasion.
  • miR-27a-5p expression correlated with the effectiveness of postoperative TSH suppression therapy.

Conclusions:

  • miR-27a-5p is downregulated in DTC and acts as a tumor suppressor.
  • Targeting SREBP1 by miR-27a-5p may inhibit DTC progression.
  • miR-27a-5p levels are associated with the outcome of TSH inhibitory therapy in DTC patients.
Keywords:
Differentiated thyroid cancerMalignant progressionMiR-27a-5pSREBP1TSH inhibition therapy

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.5K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K